BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30396854)

  • 1. A systematic review comparing radiation toxicity after various endorectal techniques.
    Verrijssen AS; Opbroek T; Bellezzo M; Fonseca GP; Verhaegen F; Gerard JP; Sun Myint A; Van Limbergen EJ; Berbee M
    Brachytherapy; 2019; 18(1):71-86.e5. PubMed ID: 30396854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy?
    Garfinkle R; Lachance S; Vuong T; Mikhail A; Pelsser V; Gologan A; Morin NA; Vasilevsky CA; Boutros M
    Dis Colon Rectum; 2019 Mar; 62(3):294-301. PubMed ID: 30741768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.
    Rijkmans EC; Marijnen CAM; van Triest B; Ketelaars M; Cats A; Inderson A; van den Ende RPJ; Laman MS; Kerkhof EM; Nout RA
    Radiother Oncol; 2019 Apr; 133():176-182. PubMed ID: 30935576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
    Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
    Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients.
    Chiang CL; Lee SF; Lee VW; Yeung CS; Cheung SK; Poon MC; Foo DC; Lo SH; Lam KO; Lee FA; Wong FC; Chan MK
    Strahlenther Onkol; 2020 Nov; 196(11):993-997. PubMed ID: 32313964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
    Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
    Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients.
    Chuong MD; Fernandez DC; Shridhar R; Hoffe SE; Saini A; Hunt D; Meredith KL; Biagioli MC
    Brachytherapy; 2013; 12(5):457-62. PubMed ID: 23707855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose rate brachytherapy as a boost after preoperative chemoradiotherapy for more advanced rectal tumours: the Clatterbridge experience.
    Sun Myint A; Lee CD; Snee AJ; Perkins K; Jelley FE; Wong H
    Clin Oncol (R Coll Radiol); 2007 Nov; 19(9):711-9. PubMed ID: 17884396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
    Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
    Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy.
    Serrano N; Moghanaki D; Asher D; Karlin J; Schutzer M; Chang M; Hagan MP
    Brachytherapy; 2016; 15(4):435-441. PubMed ID: 27180124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer.
    Vuong T; Devic S; Podgorsak E
    Clin Oncol (R Coll Radiol); 2007 Nov; 19(9):701-5. PubMed ID: 17714925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study.
    Vuong T; Belliveau PJ; Michel RP; Moftah BA; Parent J; Trudel JL; Reinhold C; Souhami L
    Dis Colon Rectum; 2002 Nov; 45(11):1486-93; discussion 1493-5. PubMed ID: 12432296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.